WO2009056288A3 - Statines stabilisées - Google Patents

Statines stabilisées Download PDF

Info

Publication number
WO2009056288A3
WO2009056288A3 PCT/EP2008/009123 EP2008009123W WO2009056288A3 WO 2009056288 A3 WO2009056288 A3 WO 2009056288A3 EP 2008009123 W EP2008009123 W EP 2008009123W WO 2009056288 A3 WO2009056288 A3 WO 2009056288A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
stabilized
statins
pharmaceutical composition
rosuvastatin
Prior art date
Application number
PCT/EP2008/009123
Other languages
German (de)
English (en)
Other versions
WO2009056288A2 (fr
Inventor
Renz Jessica
Thomas Rillmann
Christof Schumann
Original Assignee
Stada Arzneimittel Ag
Renz Jessica
Thomas Rillmann
Christof Schumann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stada Arzneimittel Ag, Renz Jessica, Thomas Rillmann, Christof Schumann filed Critical Stada Arzneimittel Ag
Priority to EP08843504A priority Critical patent/EP2214648A2/fr
Publication of WO2009056288A2 publication Critical patent/WO2009056288A2/fr
Publication of WO2009056288A3 publication Critical patent/WO2009056288A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Abstract

L'invention concerne une composition pharmaceutique qui contient un mélange comprenant un granulat de base composé d'au moins un adjuvant pharmaceutiquement acceptable, de l'atorvastatine ou de la rosuvastatine ou des sels pharmaceutiquement acceptables de ces principes actifs, ainsi qu'éventuellement d'autres adjuvants pharmaceutiquement acceptables. Cette composition pharmaceutique se caractérise notamment en ce que le principe actif qu'elle contient est stabilisé sous une forme cristalline métastable ou amorphe.
PCT/EP2008/009123 2007-10-30 2008-10-29 Statines stabilisées WO2009056288A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08843504A EP2214648A2 (fr) 2007-10-30 2008-10-29 Statines stabilisées

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE200710052071 DE102007052071A1 (de) 2007-10-30 2007-10-30 Stabilisiertes Atorvastatin
DE102007052071.0 2007-10-30

Publications (2)

Publication Number Publication Date
WO2009056288A2 WO2009056288A2 (fr) 2009-05-07
WO2009056288A3 true WO2009056288A3 (fr) 2009-06-18

Family

ID=40427352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/009123 WO2009056288A2 (fr) 2007-10-30 2008-10-29 Statines stabilisées

Country Status (3)

Country Link
EP (1) EP2214648A2 (fr)
DE (1) DE102007052071A1 (fr)
WO (1) WO2009056288A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114569803B (zh) 2020-11-30 2023-10-03 财团法人工业技术研究院 抗卷曲薄膜

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071402A2 (fr) * 2003-02-12 2004-08-26 Lek Pharmaceuticals D.D. Forme pharmaceutique stable comprenant un inhibiteur de reductase hmg-coa
WO2004110409A1 (fr) * 2003-06-12 2004-12-23 Warner-Lambert Company Llc Compositions pharmaceutiques d'atorvastatine
EP1532975A1 (fr) * 2003-11-18 2005-05-25 Helm AG Procédé pour la préparation d' adsorbats d'atorvastatine pulverulents à écoulement libre
WO2005084670A1 (fr) * 2004-03-01 2005-09-15 Lek Pharmaceuticals D.D. Formulation pharmaceutique

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE178794T1 (de) 1993-01-19 1999-04-15 Warner Lambert Co Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
BR9609872A (pt) 1995-07-17 1999-03-23 Warner Lambert Co Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
CN1190185C (zh) * 1999-04-06 2005-02-23 埃迪克埃迪法姆药品实验室 可饮用布洛芬药物悬浮液
SK16982002A3 (sk) 2000-06-09 2003-04-01 Lek Pharmaceuticals D. D. Stabilizovaná farmaceuticky účinná kompozícia a liečivý prípravok túto kompozíciu obsahujúci
AP1571A (en) 2001-06-29 2006-02-10 Warner Lambert Co Crystalline forms of 'R-(R* ,R*)!-2-(4- fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
WO2005084669A1 (fr) * 2004-03-01 2005-09-15 Lek Pharmaceuticals D.D. Composition pharmaceutique
MX2007000765A (es) 2004-07-20 2007-03-28 Warner Lambert Co Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1).
WO2006070248A1 (fr) * 2004-12-28 2006-07-06 Ranbaxy Laboratories Limited Procedes permettant de preparer des formes posologiques pharmaceutiques solides et stables a base d'atorvastatine et d'amlodipine
WO2008048704A2 (fr) 2006-03-10 2008-04-24 Stc.Unm Croissance pulsée de nanofils de gan, et applications dans des matériaux de substrat semi-conducteur de nitrure du groupe iii, et dispositifs de substrat
US8962130B2 (en) 2006-03-10 2015-02-24 Rohr, Inc. Low density lightning strike protection for use in airplanes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071402A2 (fr) * 2003-02-12 2004-08-26 Lek Pharmaceuticals D.D. Forme pharmaceutique stable comprenant un inhibiteur de reductase hmg-coa
WO2004110409A1 (fr) * 2003-06-12 2004-12-23 Warner-Lambert Company Llc Compositions pharmaceutiques d'atorvastatine
EP1532975A1 (fr) * 2003-11-18 2005-05-25 Helm AG Procédé pour la préparation d' adsorbats d'atorvastatine pulverulents à écoulement libre
WO2005084670A1 (fr) * 2004-03-01 2005-09-15 Lek Pharmaceuticals D.D. Formulation pharmaceutique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHRAFY ET AL: "Predictions of tensile strength of binary tablets using linear and power law mixing rules", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 333, no. 1-2, 24 February 2007 (2007-02-24), pages 118 - 126, XP005904210, ISSN: 0378-5173 *
ROWE R C ET AL: "CELLULOSE, MICROCRYSTALLINE", HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, LONDON : PHARMACEUTICAL PRESS.; GB, 1 January 2006 (2006-01-01), pages 132 - 135, XP002520963, ISBN: 978-1-58212-058-4 *

Also Published As

Publication number Publication date
DE102007052071A1 (de) 2009-05-07
WO2009056288A2 (fr) 2009-05-07
EP2214648A2 (fr) 2010-08-11

Similar Documents

Publication Publication Date Title
EP1790637A4 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
TW200716628A (en) Novel compounds
WO2006054308A3 (fr) Formulations d'atorvastatine stables
WO2007060140A3 (fr) Inhibiteurs de diacylglycérol acyltransférase (dgat)
ATE489078T1 (de) Pharmazeutische zusammensetzungen mit rosuvastatin-calcium
WO2007127158A3 (fr) Modification d'absorption percutanée de matériaux topiquement actifs
IL188438A (en) A heterocyclic active drug with five benzoposes, or a pharmaceutically acceptable salt and aster salts product, as well as compounds containing them and their use as @catol - o @ - @ of @ enzyme @ dead G iltransferase @@ comtI
IL182255A0 (en) Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
DK1608362T3 (da) Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse
WO2007009806A3 (fr) Formulations posologiques solides de medicaments narcotiques presentant une adsorption buccale amelioree
EP2102225A4 (fr) Dérivés d'alpha-galactosylceramide, sels pharmaceutiquement acceptables de ceux-ci, procédé de préparation et composition pharmaceutique d'adjuvant immunologique contenant ces composés comme principe actif
EP1619180A4 (fr) ANTAGONISTE DE CaSR
WO2008062476A3 (fr) Composition pharmaceutique comprenant de la rosuvastatine ou un sel de qualité pharmaceutique de cette substance
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
EP2011492A4 (fr) INHIBITEURS DE LA SÉCRÉTION dU GIP
EP1731609A4 (fr) INHIBITEUR DE L'EXPRESSION DE Rad51, MÉDICAMENT CONTENANT L'INHIBITEUR COMME INGRÉDIENT ACTIF ET UTILISATION DE CELUI-CI
WO2007099171A3 (fr) Bicyclopyrazoles actifs comme inhibiteurs de la kinase
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
EP1883619B8 (fr) Methode de preparation d'un compose tetrafluorobenzylaniline substitue et de ses sels pharmaceutiquement acceptables
ZA200701443B (en) Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
IL183163A0 (en) Sulfonamido-macrocycles as tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
WO2008101173A3 (fr) Compositions et matériaux biodégradables
WO2008020314A3 (fr) Formulations de dosage stabilisantes à base de statine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08843504

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008843504

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE